Replies to post #113543 on Biotech Values

[biomaven0]

Well the recent bad news on Iniparib is pretty ironic given they just published their very successful Ph II in the NEJM:

http://www.nejm.org/doi/full/10.1056/NEJMoa1011418

But note there was an accompanying editorial critical of this trial - imbalances, etc.

Note also in this latest trial there seemed to be a signal in relapsed disease, so it's not quite dead yet - I believe they are now looking at ovarian.

There are a bunch of ongoing trials (notably Abbott) in this class - Iniparib is I think the weakest inhibitor in the class, but there may well be tox issues with the more potent drugs.

Peter

[jq1234]

Myriad Genetics Falls After Sanofi Setback Dims Prospects for Drug Testing

[It seems the infatuation with PARP inhibitor is fading. There might still be usage in some capacity, but the scope of usage will be dramatically reduced.]

http://www.bloomberg.com/news/2011-01-28/myriad-genetics-falls-after-sanofi-setback-dims-prospects-for-drug-testing.html

[genisi]

I thought the PARP inhibitors class was the most promising new anti cancer therapy and that they could at least allow to reduce the doses of some chemotherapy agents in treating tumors with homologous recombination deficiency, such as BRCA1/2. There’s still hope that the the concept is correct in specific cancer mutated population.